Capstan Therapeutics

Capstan Therapeutics was founded with the mission to advance precision in vitro and in vivo cell engineering, aiming to develop therapeutics for a wide range of diseases that currently have unmet or underserved clinical needs. The company focuses on innovative cell engineering techniques to create targeted treatments, leveraging cutting-edge technologies to address complex medical challenges. Their market focus includes developing therapies for conditions such as cardiac fibrosis and enhancing CAR T cell therapies.

Notable affiliated individuals include leading scientists and industry experts who contribute to Capstan's pioneering research. The company has garnered attention through significant publications in esteemed journals like Science and The New England Journal of Medicine. Key achievements include advancements in mRNA delivery for hematopoietic stem cell modification and CAR T cell therapies. Capstan Therapeutics is making a substantial impact by pushing the boundaries of cell engineering to offer new hope for patients with critical medical needs.